Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cara Therapeutics, Inc. (CARA)
|
Add to portfolio |
|
|
|
| Price: |
$12.65
| | Metrics |
| OS: |
54.1
|
M
| |
|
|
| Market cap: |
$684
|
M
| |
|
|
|
Net cash:
|
$58.2
|
M
| |
$1.08
|
per share
|
|
EV:
|
$626
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($87.2)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 41.9 | 23.0 | 135.1 | 19.9 | 13.5 | 0.9 | 0.1 | 3.8 |
| Revenue growth | 81.8% | -83.0% | 579.3% | 47.6% | 1378.5% | 959.3% | -97.7% | 19.7% |
| Cost of goods sold | 7.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 34.6 | 23.0 | 135.1 | 19.9 | 13.5 | 0.9 | 0.1 | 3.8 |
| Gross margin | 82.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 91.9 | 82.7 | 107.9 | 113.8 | 75.5 | 48.5 | 49.3 | 21.2 |
| General and administrative | 30.3 | 29.4 | 21.8 | 17.7 | 15.3 | 11.9 | 9.2 | 7.8 |
| EBIT | -87.5 | -89.1 | 5.4 | -111.7 | -77.4 | -59.5 | -58.4 | -25.2 |
| EBIT margin | -209.1% | -386.8% | 4.0% | -561.6% | -574.5% | -6529.6% | -67907.0% | -662.3% |
| Pre-tax income | -85.5 | -88.4 | 7.7 | -107.2 | -74.4 | -58.3 | -57.7 | -25.1 |
| Income taxes | 0.0 | 0.0 | -0.7 | -0.8 | -0.4 | -0.2 | -0.5 | -0.4 |
| Tax rate | 0.0% | 0.0% | | 0.8% | 0.5% | 0.3% | 0.8% | 1.6% |
| Net income | -85.5 | -88.4 | 8.4 | -106.4 | -74.0 | -58.1 | -57.3 | -24.7 |
| Net margin | -204.2% | -384.1% | 6.2% | -534.9% | -549.5% | -6380.4% | -66604.7% | -649.2% |
| |
| Diluted EPS | ($1.59) | ($1.74) | $0.18 | ($2.49) | ($2.06) | ($1.86) | ($2.10) | ($1.00) |
| Shares outstanding (diluted) | 53.7 | 50.7 | 47.9 | 42.7 | 35.9 | 31.2 | 27.3 | 24.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|